美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

ALPS Medical Breakthroughs ETF

62.20

-1.5276-2.40%

盤後：62.12-0.0806-0.13%19:30 EDT

成交量：1.95萬

成交額：121.45萬

市值：2.25億

市盈率：- -

高：63.39

開：63.10

低：61.96

收：63.73

52周最高：70.85

52周最低：36.32

股本：362.50萬

流通股本：362.50萬

量比：0.41

換手率：0.54%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

重温-美國股市：三大指數升跌互現，指標公債收益率升破5%

美國股市：三大指數升跌互現，指標公債收益率升破5%

Xenon製藥美股盤前跌超28%

Xenon製藥盤前股價暴跌27.5%，因暫停抑鬱症藥物試驗新患者招募

Xenon製藥提交Azetukalner新藥申請至FDA用於局灶性癲癇，並更新精神科臨床項目進展

阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。

109億美元重磅收購Apogee(APGE.US)落地！艾伯維(ABBV.US)完成2019年以來最大併購，預計2032年起貢獻收益

109億美元重磅收購Apogee(APGE.US)落地！艾伯維(ABBV.US)完成2019年以來最大併購，預計2032年起貢獻收益

美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極

藥聞 | 英硅智能上市後首份半年報扭虧創新藥研發加速擁抱AI

聯環藥業上半年扭虧為盈集採續採與創新藥研發協同推進

博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑

中國銀河證券：實驗動物為創新藥研發剛需小鼠+猴雙主線高景氣

百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務不涉及創新藥研發

百花醫藥(600721.SH)：不涉及創新藥研發

百花醫藥(600721.SH)：不涉及創新藥研發

東方證券：AI重構創新藥研發底座國內相關產業鏈公司亦有望受益

券商觀點：艾伯維免疫學研發管線實力雄厚，將支撐營收增長

艾伯維因收購Apogee下調2026年盈利預期，第二季度業績超出預期

《健康快訊》：實驗性細胞療法可延緩杜氏肌營養不良症患者心力衰竭的進展

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/SBIO/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"SBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBIO\",,,,,undefined,":{"symbol":"SBIO","market":"US","secType":"STK","nameCN":"ALPS Medical Breakthroughs ETF","latestPrice":62.2006,"timestamp":1789761600000,"preClose":63.7282,"halted":0,"volume":19490,"hourTrading":{"tag":"盘后","latestPrice":62.12,"preClose":62.2006,"latestTime":"19:30 EDT","volume":18,"amount":1107.3954,"timestamp":1789774205561,"change":-0.0806,"changeRate":-0.001296,"amplitude":0},"delay":0,"changeRate":-0.023970549929230697,"floatShares":3625000,"shares":3625000,"eps":0,"marketStatus":"休市中","change":-1.5276,"latestTime":"09-18 16:00:00 EDT","open":63.1,"high":63.385,"low":61.96,"amount":1214539.54164,"amplitude":0.022361,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":63.7282,"sharesOutstanding":2675000,"nav":62.25,"aum":225655960.35,"bidAskSpread":0.002808,"postHourTrading":{"tag":"盘后","latestPrice":62.12,"preClose":62.2006,"latestTime":"19:30 EDT","volume":18,"amount":1107.3954,"timestamp":1789774205561,"change":-0.0806,"changeRate":-0.001296,"amplitude":0},"volumeRatio":0.4133107687792956,"impliedVol":0.2645,"impliedVolPercentile":0.8446},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBIO\",,,,,undefined,":{"symbol":"SBIO","floatShares":3625000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.4133107687792956,"shares":3625000,"dividePrice":0,"high":63.385,"amplitude":0.022361,"preClose":63.7282,"low":61.96,"week52Low":36.32,"pbRate":"--","week52High":70.85,"institutionHeld":0,"latestPrice":62.2006,"eps":0,"divideRate":0,"volume":19490,"delay":0,"ttmEps":0,"open":63.1,"prevYearClose":51.22,"prevWeekClose":63.29,"prevMonthClose":66.82,"prevQuarterClose":64.65,"fiveDayClose":63.29,"twentyDayClose":68.56,"sixtyDayClose":60.843},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SBIO\",params:#limit:5,,,undefined,":[{"date":"2024-12-19","symbol":"SBIO","amount":1.17346,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-19","defaultRemindTime":1734618600000,"name":"ALPS Medical Breakthroughs ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-19","currency":"USD","dateTimestamp":1734584400000,"payDate":"2024-12-26"},{"date":"2023-12-21","symbol":"SBIO","amount":0.07106,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-22","defaultRemindTime":1703169000000,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2023-12-27","payableDate":"2023-12-22","currency":"USD","dateTimestamp":1703134800000,"payDate":"2023-12-27"},{"market":"US","date":"2019-12-19","symbol":"SBIO","amount":0.01585,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2019-12-27","payableDate":"2019-12-20","currency":"USD","type":"dividend","dateTimestamp":1576731600000},{"market":"US","date":"2018-12-20","symbol":"SBIO","amount":0.78406,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2018-12-27","payableDate":"2018-12-21","currency":"USD","type":"dividend","dateTimestamp":1545282000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SBIO\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.78406,"currency":"USD"},{"executeDate":"2019-12-19","recordDate":"2019-12-20","paymentDate":"2019-12-27","value":0.01585,"currency":"USD"},{"executeDate":"2023-12-21","recordDate":"2023-12-22","paymentDate":"2023-12-27","value":0.07106,"currency":"USD"},{"executeDate":"2024-12-19","recordDate":"2024-12-19","paymentDate":"2024-12-26","value":1.17346,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SBIO\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SBIO\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669138182","title":"重温-美國股市：三大指數升跌互現，指標公債收益率升破5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669138182","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669138182?lang=zh_tw&edition=fundamental","pubTime":"2026-09-21 07:30","pubTimestamp":1789947000,"startTime":"0","endTime":"0","summary":"重温-美国股市：三大指数涨跌互现，指标公债收益率升破5%重温路透纽约9月18日-华尔街周五交投平淡，为动荡的一周画上句号。指标美国公债收益率升破5%，原油价格回吐早盘涨幅，但仍维持在每桶100美元上方，通胀担忧继续成为市场焦点。标普500指数本周微跌，科技股占比较高的纳斯达克指数收盘高于上周五。蓝筹股道琼斯工业指数则创下3月以来最大单周百分比跌幅。道琼斯工业指数.DJI下跌95.40点，跌幅0.18%，收报51,682.64点。该公司股价当日微跌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260920:nL6T45A181:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE","SBIO","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668734559","title":"美國股市：三大指數升跌互現，指標公債收益率升破5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668734559","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668734559?lang=zh_tw&edition=fundamental","pubTime":"2026-09-19 04:39","pubTimestamp":1789763948,"startTime":"0","endTime":"0","summary":"美国股市：三大指数涨跌互现，指标公债收益率升破5%路透纽约9月18日-华尔街周五交投平淡，为动荡的一周画上句号。指标美国公债收益率升破5%，原油价格回吐早盘涨幅，但仍维持在每桶100美元上方，通胀担忧继续成为市场焦点。标普500指数本周微跌，科技股占比较高的纳斯达克指数收盘高于上周五。蓝筹股道琼斯工业指数则创下3月以来最大单周百分比跌幅。道琼斯工业指数.DJI下跌95.40点，跌幅0.18%，收报51,682.64点。该公司股价当日微跌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nL6S45A169:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","XENE","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668946461","title":"Xenon製藥美股盤前跌超28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668946461","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668946461?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 16:09","pubTimestamp":1789718975,"startTime":"0","endTime":"0","summary":"【Xenon制药美股盘前跌超28%】Xenon制药美股盘前跌超28%，因公司暂停了抑郁症药物试验的新患者招募。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609183878613718.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609183878613718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SBIO","BK4139","IBRN","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106034976","title":"Xenon製藥盤前股價暴跌27.5%，因暫停抑鬱症藥物試驗新患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1106034976","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106034976?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 16:06","pubTimestamp":1789718769,"startTime":"0","endTime":"0","summary":"Xenon制药（Xenon Pharmaceuticals）盘前交易中股价大幅下挫，跌幅高达27.5%。这一剧烈波动源于该公司宣布，已决定暂停其抑郁症药物试验的新患者招募工作。市场对此消息反应迅速且激烈，投资者信心受到明显冲击。此举意味着，这家生物制药公司在推进其核心候选药物临床研发进程中，遭遇了意料之外的阻碍。尽管公司方面尚未透露暂停的具体原因，但资本市场已用脚投票，显示出对这一变数的深切担忧。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE","SBIO","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119474444","title":"Xenon製藥提交Azetukalner新藥申請至FDA用於局灶性癲癇，並更新精神科臨床項目進展","url":"https://stock-news.laohu8.com/highlight/detail?id=1119474444","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119474444?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 04:02","pubTimestamp":1789675334,"startTime":"0","endTime":"0","summary":"Xenon制药正式宣布，已就其候选药物Azetukalner向美国食品药品监督管理局提交新药申请，该药物旨在治疗局灶性癫痫。与此同时，公司还对外披露了其精神科临床项目的最新动态。此次NDA提交标志着Azetukalner在监管审批道路上迈出了关键一步。作为一款备受瞩目的在研疗法，Azetukalner的申请递交获得了业界的广泛关注，为那些饱受局灶性癫痫困扰的患者群体带来了新的希望。不仅如此，Xenon制药还借此机会，就其正在推进的精神科适应症临床开发计划提供了补充说明。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","SBIO","BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XPH","HELX","SYNB","PPH","RXL","MRNY","XBIX","BME","LU2322448791.USD","BK4585","FBT","LU2272731600.USD","LU1992135472.HKD","GNOM","LU2322448957.HKD","SBIO","PBPH","IBRN","IEHS","LU2272731865.HKD","AZNH","LU2473716301.USD","IEIH","BBP","PSCH","IYH","MEDI","PBE","TMED","BIOY","LFSC","WDNA","IBB","PJP","BK4588","CANC","IE00B5TLWC47.USD","LU2272731782.SGD","MRNX","LU1992135399.USD","IDNA","RSPH","BIB","BBH","FTXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664388058","title":"109億美元重磅收購Apogee(APGE.US)落地！艾伯維(ABBV.US)完成2019年以來最大併購，預計2032年起貢獻收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2664388058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664388058?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 09:35","pubTimestamp":1788485746,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PPH","KCE","AGNG","IE000WAW04H5.SGD","IE00B19Z3B42.SGD","LU0859254822.USD","LU2129689605.HKD","RXL","SBIO","LU0114720955.EUR","JDOC","SG9999003800.SGD","CALF","LU1839511570.USD","IYH","FHLC","IXJ","LU2089984988.USD","LU0310800379.SGD","LU2237443549.SGD","LU0234570918.USD","LU0170899867.USD","MYLD","LU0203345920.USD","GLAM","APGE","LU1267930490.SGD","LU2087621335.USD","VHT","FTXH","XLV","MEDX","LU1496350502.SGD","LU2129689514.USD","IE0002141913.USD","LU2125909593.SGD","LU0820561909.HKD","LU0128525929.USD","LU0124676726.USD","BK4533","LU1551013425.SGD","LU0069063385.USD","LU0320765646.SGD","LU1236620834.HKD","LU2237443895.HKD","PJP","TRUH","ABBV","LU2433249047.HKD","XMMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664053388","title":"109億美元重磅收購Apogee(APGE.US)落地！艾伯維(ABBV.US)完成2019年以來最大併購，預計2032年起貢獻收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2664053388","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664053388?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 09:35","pubTimestamp":1788485746,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，艾伯维于周四表示，公司已完成对抗炎药物研发商 Apogee Therapeutics价值 109 亿美元的收购。笔交易是这家制药巨头自 2019 年以来规模最大的补强型收购，智通财经AAPP于今年 6 月首次对此进行了报道。艾伯维预计，该项收购将对其调整后稀释每股收益产生负面影响，其中 2026 年将减少 0.14 美元，2027 年减少约 0.46 美元，并预计将于 2032 年开始实现增益。该指引已包含与完成 Apogee 收购相关的每股 0.14 美元稀释效应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1037948541.HKD","IE0002270589.USD","LU0057025933.USD","LU0203345920.USD","VHT","MYLD","LU1989772840.SGD","TRUH","BK4566","SG9999011175.SGD","BK4581","XLV","IYH","LU2237443549.SGD","LU1983299246.USD","LU0124676726.USD","LU0256863902.USD","LU0965509283.SGD","FHLC","IE00BN8TJ469.HKD","IE00B4R5TH58.HKD","AGNG","LU0985320562.USD","LU1003077747.HKD","IE00B19Z3581.USD","LU1718418525.SGD","IE00B2B36J28.USD","XMMO","JDOC","SBIO","MEDX","PPH","LU1934455194.USD","LU0170899867.USD","LU1236620834.HKD","BK4559","GLAM","IXJ","LU2089283258.USD","IE0004445239.USD","KCE","PJP","IE00BLSP4239.USD","CALF","FTXH","RXL","LU0289739343.SGD","ABBV","LU1093756168.USD","APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664521258","title":"美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極","url":"https://stock-news.laohu8.com/highlight/detail?id=2664521258","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664521258?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 22:18","pubTimestamp":1788272338,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BJT1NW94.SGD","LU2322448957.HKD","RXL","BK4588","IE0002141913.USD","BBP","IBRN","PBE","FTXH","HELX","SYNB","IEHS","PJP","IEIH","AZNH","LU0211331839.USD","SBIO","IE00BFTCPJ56.SGD","IBB","IE00BJJMRZ35.SGD","PBPH","NVS","XBIX","XPH","CANC","LU2473716301.USD","BIOY","MEDI","BK4585","TMED","LFSC","IDNA","BIB","MRNY","FBT","LU2272731600.USD","WDNA","GNOM","IE00B4R5TH58.HKD","IE0009355771.USD","PPH","RSPH","BK4007","BME","BBH","MEDX","MRNX","LU0070302665.USD","PSCH","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663282078","title":"藥聞 | 英硅智能上市後首份半年報扭虧 創新藥研發加速擁抱AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2663282078","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663282078?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 15:35","pubTimestamp":1788161758,"startTime":"0","endTime":"0","summary":"新华财经上海8月31日电（记者杜康）作为AI制药领域代表性企业之一，英硅智能（03696.HK）日前发布2026年度中期业绩报告。上半年，公司实现总营收1.063亿美元，同比增长287.2%；净利润3554万美元，经调整净利润5123万美元，经营活动现金流转正。这是英硅智能上市后发布的首份半年报，公司也由此前的亏损转为盈利。从收入结构看，药物研发与管线开发仍是主要来源。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860072952.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860072952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IPOS","GDOC","IBB","CHAT","AGIX","AIPO","BIOY","XLVI","SBIO","LFSC","GSKH","WRND","APXH","PBE","ARTY","BK4585","VTHR","BK4588","BBP","QTOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044177","title":"聯環藥業上半年扭虧為盈 集採續採與創新藥研發協同推進","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044177","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663044177?lang=zh_tw&edition=fundamental","pubTime":"2026-08-30 21:12","pubTimestamp":1788095520,"startTime":"0","endTime":"0","summary":"业绩实现扭亏为盈经营基本面持续改善今年上半年，联环药业经营业绩实现明显改善。对此，联环药业正持续推进相关工作。值得注意的是，联环药业已经开始围绕创新药商业化进行营销体系布局。除LH-1801外，联环药业产品注册申报也取得阶段性进展。从核心产品稳定销售，到集采品种持续放量，再到创新药研发向上市申报环节推进，联环药业正在逐步形成多层次的业务增长支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GDOC","IBB","XLVI","LFSC","PBE","BBP","WRND","GSKH","BK4585","BK0239","600513","BK4588","BIOY","APXH","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662752987","title":"博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662752987","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662752987?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:57","pubTimestamp":1787813849,"startTime":"0","endTime":"0","summary":"然而，需警惕新药研发政策变化、项目执行延期及市场竞争加剧带来的风险，同时关注经营现金流与净利润背离的情况。后续需重点关注公司在手订单转化进度、临床前及临床研究服务的毛利率变化趋势，以及经营现金流的改善情况。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787797151251328663","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4585","GSKH","BK0216","SBIO","SPHQ","PBE","BIOY","GDOC","APXH","159399","WRND","BK4588","XLVI","BBP","IBB","LFSC","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659504119","title":"中國銀河證券：實驗動物為創新藥研發剛需 小鼠+猴雙主線高景氣","url":"https://stock-news.laohu8.com/highlight/detail?id=2659504119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659504119?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 15:07","pubTimestamp":1786691225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，实验动物为创新药研发刚需，行业壁垒深厚，两大细分赛道具备中长期成长逻辑：人源化小鼠赛道成长确定性更强、周期波动平缓;实验猴赛道供给约束强，短期价格上行带来显著业绩弹性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GSKH","IBB","BK4585","WRND","601881","BK4588","161027","LFSC","XLVI","BK0276","GDOC","BK0188","BBP","06881","BIOY","BK1147","SBIO","BK1564","APXH","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903675","title":"百花醫藥股價嚴重異常波動：主營小分子化學仿製藥CRO業務 不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903675","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658903675?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541220,"startTime":"0","endTime":"0","summary":"8月12日，百花医药（维权）（600721.SH）发布公告称，公司股票连续10个交易日内日收盘价格涨幅偏离值累计超过100%，根据上交所的有关规定，属于股票交易严重异常波动情形。公司是以小分子化学仿制药研发为主的CRO企业，不涉及创新药研发。公司2026年第一季度实现营业收入6718.29万元，同比下降30.68%，归属于上市公司股东的净利润664.27万元，同比下降67.94%。目前公司主营业务未发生重大变化，市场环境、行业政策没有发生重大调整，股价短期内连续上涨，涨幅与公司经营情况严重偏离。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-12/doc-ininamih5206238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","600721","GSKH","BK0102","BK0216","WRND","BK4585","GDOC","PBE","APXH","SBIO","XLVI","IBB","BBP","BIOY","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658692990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PBE","SBIO","BBP","IBB","GSKH","XLVI","BK4585","LFSC","WRND","BK4588","BIOY","APXH","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658667990","title":"百花醫藥(600721.SH)：不涉及創新藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658667990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658667990?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百花医药(600721.SH)发布股票交易风险提示公告称，公司是以小分子化学仿制药研发为主的CRO企业，主营业务是为客户提供小分子化仿药为主的药物研发注册“一站式”全流程服务，主要研发项目多来自于客户委托加部分的公司自主立项，不涉及创新药研发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","WRND","BK0102","600721","XLVI","BK4588","SBIO","BBP","APXH","BIOY","LFSC","BK0216","GDOC","PBE","IBB","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658962968","title":"東方證券：AI重構創新藥研發底座 國內相關產業鏈公司亦有望受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2658962968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658962968?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 14:06","pubTimestamp":1786428403,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：技术颠覆成本，AI重构制药“快与省”是中国创新药崛起的底层逻辑，根基是人才红利和成本优势。专家与AI协同，将真正提升新药研发的成功率并缩短周期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","IBB","LFSC","ARTY","BK0276","AIPO","BK1564","BK0183","QTOC","BK0028","GSKH","WRND","CHAT","03958","XLVI","BK4585","BK1147","APXH","AGIX","BK0188","BBP","BIOY","SBIO","VTHR","PBE","BK0012","600958","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656375158","title":"券商觀點：艾伯維免疫學研發管線實力雄厚，將支撐營收增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2656375158","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656375158?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 19:32","pubTimestamp":1785756750,"startTime":"0","endTime":"0","summary":"BUZZ-券商观点：艾伯维免疫学研发管线实力雄厚，将支撑营收增长8月3日-** 艾伯维（AbbVie）ABBV.N周五略微下调了其2026年盈利预期 (link)，以反映其计划收购Apogee Therapeutics的交易；同时，得益于免疫学药物销售强劲，该公司第二季度业绩超出市场预期免疫学业务表现稳健** Canaccord Genuity(维持“买入”评级，目标价：290美元) 指出，艾伯维","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL4S4400YQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF631.EUR","LU0661504455.SGD","LU0912757837.SGD","LU1551013425.SGD","RXL","LU0053671581.USD","GLAM","LU1267930490.SGD","VHT","AGNG","SBIO","APGE","FTXH","LU0965508806.USD","LU0726765562.USD","IE00BJJMRZ35.SGD","LU1267930573.SGD","BK4533","LU0057025933.USD","TRUH","LU0689472784.USD","IXJ","MEDX","IE00BLSP4452.SGD","IE0004445239.USD","LU2089283258.USD","FHLC","LU1093756325.SGD","LU1496350171.SGD","PPH","LU0211327993.USD","PJP","LU1003077747.HKD","XLV","LU0203345920.USD","IYH","SG9999003800.SGD","ABBV","LU1093756168.USD","LU1989772923.USD","BK4534","JDOC","LU0417517546.SGD","IE00BVYPNV92.GBP","LU0198837287.USD","LU2237443978.SGD","LU0472753341.HKD","LU1670627923.USD","LU1061106388.HKD","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655365569","title":"艾伯維因收購Apogee下調2026年盈利預期，第二季度業績超出預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2655365569","media":"路透中文","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655365569?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 19:49","pubTimestamp":1785498540,"startTime":"0","endTime":"0","summary":"艾伯维因收购Apogee下调2026年盈利预期，第二季度业绩超出预期预计2026年每股收益将因计划中的Apogee收购交易而减少14美分季度营收超出预期，达到169.9亿美元Humira销售额下滑36%至7.56亿美元，仍高于市场预期Skyrizi和Rinvoq的业绩也超出预期路透7月31日-艾伯维ABBV.N周五下调了2026年的盈利预期，以反映其计划收购Apogee Therapeutics的影响，同时得益于免疫学药物销售强劲，其第二季度业绩超出市场预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL4S43X1CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1670628061.USD","MEDX","SBIO","IE000BZT7R73.USD","IE0002141913.USD","IE000MB6IJN5.SGD","LU2089984988.USD","LU0965509283.SGD","LU2347655156.SGD","LU0820561909.HKD","LU1061106388.HKD","RXL","IE00BSNM7G36.USD","JDOC","LU0689626769.HKD","LU1551013425.SGD","XLV","SG9999015945.SGD","LU0203347892.USD","LU0689472784.USD","IXJ","LU0738911758.USD","LU2129689431.USD","SG9999001440.SGD","PJP","LU1037948541.HKD","APGE","SG9999015952.SGD","BK4559","LU1732800096.USD","LU0211328371.USD","IE00B19Z3B42.SGD","LU1839511570.USD","PPH","LU0170899867.USD","VHT","FHLC","GLAM","IYH","IE00BVYPNW00.USD","ABBV","LU1718418525.SGD","TRUH","BK4588","IE00BFTCPJ56.SGD","LU2087621335.USD","AGNG","FTXH","LU0456855351.SGD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655480022","title":"《健康快訊》：實驗性細胞療法可延緩杜氏肌營養不良症患者心力衰竭的進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2655480022","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655480022?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 02:56","pubTimestamp":1785437766,"startTime":"0","endTime":"0","summary":"研究人员表示，这些数据标志着首次有治疗方法被证实不仅能减缓或阻止上肢功能的丧失，还能延缓杜氏肌营养不良症患儿及年轻男性患者心力衰竭的进展。杜氏肌营养不良症是一种遗传性疾病，会导致全身肌肉逐渐萎缩，而心力衰竭往往会导致患者过早死亡。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nL4S43W2K6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPR","BK4139","SBIO","CGON"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":25,"code":"91000000","status":"200"}]}}